Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen’s Anemia Drugs Weaken In First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

“Trust us” on unchanged revenue guidance, CEO says.
Advertisement

Related Content

CHMP Recommends Three Approvals And Two Label Expansions, Makes One Denial
CHMP Recommends Three Approvals And Two Label Expansions, Makes One Denial
Amgen’s Aranesp Gets Broader Label
Amgen’s Aranesp Gets Broader Label
Roche Agrees To Court Conditions For Mircera Launch
Amgen’s Aranesp, Procrit CIA Indications Okay For Incurable Cancers - ODAC
Amgen’s Aranesp, Procrit CIA Indications Okay For Incurable Cancers - ODAC
Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis

Topics

Advertisement
UsernamePublicRestriction

Register

PS067649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel